Kisunla access in Saudi Arabia: the SFDA named-patient pathway
How Saudi Arabia patients legally obtain Kisunla (donanemab-azbt) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Kisunla (donanemab-azbt) is a humanised IgG1 monoclonal antibody directed against pyroglutamate-modified amyloid beta peptide deposited as insoluble plaque. It received traditional FDA approval in July 2024 for the treatment of Alzheimer's disease, specifically for adults with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease dementia, with biomarker-confirmed amyloid pathology. Standard dosing is 700 mg administered intravenously every 4 weeks for the first three infusions, then 1,400 mg every 4 weeks. A distinguishing feature of Kisunla is that the FDA label allows discontinuation once amyloid plaque clearance is confirmed by amyloid PET, which can occur as early as 6 to 12 months of therapy in approximately half of treated patients. The drug's label carries a boxed warning for amyloid-related imaging abnormalities (ARIA), with risk stratified by APOE epsilon-4 genotype. MRI surveillance prior to infusions 2, 3, 4, and 7 is the protocol baseline, with additional MRIs as clinically indicated. Saudi Arabia families pursuing Kisunla through the named-patient pathway are typically working around one of three local gaps: the drug is not registered in Saudi Arabia at all, or it is registered but not currently stocked, or it is registered and stocked but the patient is unable to clear payer or formulary requirements within a clinically acceptable timeframe. Reserve Meds coordinates the US-side sourcing through a DSCSA-compliant specialty channel, the cold-chain (or, where applicable, cryogenic) logistics, and the documentation packet your physician submits to the Saudi Food and Drug Authority (SFDA).
Reserved for you.
Why Saudi Arabia patients need Kisunla through the named-patient pathway
Saudi Arabia operates a centralised pharmaceutical regulatory environment under the Saudi Food and Drug Authority (SFDA), established under Royal Decree in 2003. The SFDA administers marketing authorisations, GMP inspections, pharmacovigilance, and the Special Access Pathway through which named-patient imports are processed. Vision 2030 healthcare reforms have expanded specialty access through National Center for Mental Health Promotion, the Council of Health Insurance, and the Ministry of Health tertiary referral network. Until the 2023-2024 anti-amyloid antibody approvals, Alzheimer's disease had no disease-modifying therapy. Leqembi (lecanemab) received traditional FDA approval in July 2023 with biweekly IV dosing and a target on soluble protofibrils and insoluble fibrils. Kisunla (donanemab) received traditional FDA approval in July 2024 with monthly IV dosing, a target on deposited plaque, and the distinguishing feature of label-permitted discontinuation once amyloid plaque clearance is confirmed. The two products together establish the anti-amyloid antibody class as the first disease-modifying option for early Alzheimer's disease and are reshaping the standard of care alongside symptomatic agents (cholinesterase inhibitors and memantine).
For Kisunla specifically, three converging patterns drive Saudi Arabia cases. First, indication or product lag. Originator specialty medicines like Kisunla (donanemab-azbt) reach local registration in Saudi Arabia months to years after FDA approval, and in many cases the FDA-labelled indication, the specific product configuration, or the manufacturing slot for the patient is not locally available. Second, payer or formulary constraint. Bupa Arabia, Tawuniya, MedGulf, Al Rajhi Takaful, and the government Council of Health Insurance scheme each assess high-cost specialty therapies case by case, and a patient who clinically fits the FDA label can still face an uncovered claim or a step-therapy denial that consumes weeks the disease will not wait through. Third, brand-specific clinical reasoning. The treating neurologist or memory-disorders specialist may have made a deliberate decision based on the patient's phenotype, prior-therapy exposure, or comorbidity profile, and substituting a different molecule simply because it is what the local pharmacy stocks is not the right clinical call.
In each pattern, the named-patient pathway is the legal mechanism that connects a Saudi Arabia-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific identified patient. It is not a workaround; it is the framework the regulator has established for precisely these gaps.
The SFDA named-patient pathway for Kisunla
The SFDA Special Access Pathway, often described as the Compassionate Use or Named-Patient Import pathway, allows MOH and private hospitals to import medicines that are not yet SFDA-registered or not currently available through registered channels, for a specific named patient. The medicine must be approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, Health Canada, or TGA Australia) and a clinically equivalent locally registered alternative must be unsuitable. Applications route through the SFDA e-services portal (sfda.gov.sa) under the personal import or compassionate use module. For Kisunla specifically, the clinical justification typically frames the case around the precise FDA-approved indication and the documented gap in the local route.
A complete application includes a clinical justification letter from the treating physician (diagnosis, severity, prior therapies, why this specific drug, why the locally stocked option is not suitable for this case), the treating physician's license verification through the Saudi Commission for Health Specialties (SCFHS), an anonymised patient identifier where the SFDA submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy or cell-therapy laboratory in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing facility, including cold-chain or cryogenic handling specific to the product format.
Kisunla is indicated for the treatment of Alzheimer's disease in adults with mild cognitive impairment (MCI) or mild dementia stage, with confirmed amyloid pathology by amyloid PET imaging or cerebrospinal fluid (CSF) biomarkers. The drug is not indicated for moderate or severe Alzheimer's, for non-Alzheimer's dementia, or for patients without amyloid biomarker confirmation. The clinical justification for Kisunla typically documents the specific indication criterion that the patient meets, the prior-therapy history that establishes label eligibility, and the operational plan at the treating hospital.
SFDA routine processing for Special Access Pathway applications is typically 10 to 20 business days from a complete submission. Complex first-time imports of high-acuity products can extend to 6 to 8 weeks. The SFDA retains discretion on timing.
Where Kisunla gets dispensed in Saudi Arabia
A focused group of Saudi Arabia institutions handle named-patient imports of high-acuity specialty products as established workflow, with the in-house clinical, pharmacy, and (where relevant) cell-therapy laboratory infrastructure and neurologists and memory-disorders specialists experienced with both the clinical management and the SFDA application set. Biomarker-confirmed amyloid pathology (amyloid PET or CSF Abeta42/40 and phospho-tau), APOE genotyping (with informed consent and a clear plan for ARIA risk stratification), baseline brain MRI within the prior 12 months, monthly IV infusion logistics, an MRI surveillance schedule (typically before infusions 2, 3, 4, and 7), serial amyloid PET imaging at 6-month and 12-month intervals to assess plaque clearance and trigger discontinuation, anti-coagulant and antiplatelet co-prescription review, and a multidisciplinary plan for ARIA detection and management are the operational pillars of a Kisunla case.
Tertiary and major private hospitals that have demonstrated the capability for Kisunla-class therapy in Saudi Arabia include King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh and Jeddah neurology services, King Abdulaziz Medical City (NGHA) Riyadh and Jeddah neurology and memory clinics, King Fahad Medical City Riyadh, King Khaled University Hospital Riyadh, King Abdulaziz University Hospital Jeddah, Dr. Sulaiman Al Habib Hospital memory and neurology services across Riyadh, Jeddah, and Khobar, and Saudi German Hospital neurology departments.
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a licensed pharmaceutical establishment or a tertiary referral hospital that holds the necessary SFDA relationship and files the application on the prescribing physician's behalf. The medicine then moves into the treating hospital's pharmacy under documented chain-of-custody.
Real cost picture for Kisunla in Saudi Arabia
US WAC for Kisunla is approximately USD 32,500 per year for the standard monthly IV dosing in an adult of average weight, with annualised total cost of care (including biomarker workup, MRI surveillance, infusion centre fees, amyloid PET imaging for discontinuation assessment, and pre-infusion clinical visits) often USD 42,000 to USD 75,000 in the United States. The label-permitted discontinuation feature means many patients receive Kisunla for 12 to 18 months rather than indefinitely.. The SAR/USD conversion (SAR is pegged to USD at approximately 3.75 to 1) means the annual US WAC for Kisunla translates to roughly SAR 122,000 per year at the SAR/USD peg, with total cost of care for a complete year of monthly infusions plus surveillance imaging often SAR 160,000 to SAR 280,000 at reference rates. These figures are US WAC reference points only; manufacturer pricing on cross-border named-patient supply may differ from US WAC, and Reserve Meds' firm quote on a specific case reflects negotiated supply pricing rather than US list.
International logistics for a cold-chain biologic shipment to Saudi Arabia typically runs USD 500 to USD 1,800 (approximately SAR 1,900 to SAR 6,800) depending on destination city, urgency, and pack size. SFDA permit fees are nominal relative to drug cost; customs duties on personal-import medicines are generally waived on physician-attested medical necessity. For Kisunla specifically, Kisunla is a refrigerated (2 to 8 degrees Celsius) monoclonal antibody supplied in single-dose vials. Validated thermal packaging with continuous temperature logging is the operational standard for the cross-border shipping leg. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the insurance side, each Saudi insurer assesses Special Access Pathway imports case by case. The Council of Health Insurance (CHI) drug formulary expansion has improved specialty biologic coverage for citizens and residents in the private cooperative health insurance pool. Bupa Arabia and Tawuniya hold the largest specialty pharmacy networks and often have the most established pre-authorisation workflow. We do not promise coverage from any insurer; we supply the documentation set that lets your insurer assess the case.
Typical timeline for Kisunla in Saudi Arabia
SFDA routine processing for a Kisunla application from a complete submission typically tracks the regulator's standard window. For Kisunla specifically, the manufacturing or sourcing pathway adds an additional dimension beyond the regulator timeline. Drug sourcing through a DSCSA-compliant specialty distributor, validated cold-chain packaging, and customs clearance scheduled to avoid extreme temperature exposure are the operational steps that translate a regulatory approval into a delivered dose. End-to-end, most adult cases complete within 4 to 8 weeks from first complete documentation, depending on regulator queue and shipping lane.
We do not promise specific case timelines. Saudi Food and Drug Authority (SFDA) retains discretion on application review, manufacturers retain discretion on slot allocation and supply, and shipping lanes are subject to customs and weather. The figures above describe typical experience at experienced centres, not contractual commitments.
What your physician needs to provide
For a Saudi Arabia-licensed neurologist or memory-disorders specialist prescribing Kisunla through the SFDA pathway, the clinical justification letter is the cornerstone of the application. For Kisunla, the clinical justification letter typically documents the patient's clinical diagnosis (mild cognitive impairment due to AD or mild Alzheimer's dementia per NIA-AA criteria), the biomarker confirmation method (amyloid PET imaging or CSF Abeta42/40 ratio and phospho-tau181), baseline cognitive testing (MMSE, MoCA, or CDR Sum of Boxes), the APOE genotype with informed consent for testing, the baseline brain MRI report within the prior 12 months (assessing pre-existing microhaemorrhages, superficial siderosis, and other ARIA-relevant findings), the planned MRI surveillance schedule, and the planned amyloid PET imaging schedule for discontinuation assessment. The letter also documents any anticoagulant or antiplatelet therapy and the prescriber's plan for managing this in the context of ARIA risk.
The physician's SCFHS license number and treating hospital MOH license, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. Reserve Meds supplies a template clinical justification letter populated with the FDA-label criteria, the prior-therapy framing, and the chain-of-custody specifics; the treating physician edits to the patient's actual case and signs.Common questions about Kisunla in Saudi Arabia
Will my Saudi Arabia insurer cover this? On the insurance side, each Saudi insurer assesses Special Access Pathway imports case by case. The Council of Health Insurance (CHI) drug formulary expansion has improved specialty biologic coverage for citizens and residents in the private cooperative health insurance pool. Bupa Arabia and Tawuniya hold the largest specialty pharmacy networks and often have the most established pre-authorisation workflow. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital. We do not promise coverage from any insurer.
How is Kisunla different from Leqembi? Both are FDA-approved anti-amyloid monoclonal antibodies for early Alzheimer's disease. Kisunla targets pyroglutamate-modified amyloid beta deposited as plaque, dosed monthly IV. Leqembi targets soluble protofibrils and insoluble fibrils, dosed biweekly IV. Kisunla's distinguishing feature is the FDA-label provision for discontinuation once amyloid plaque clearance is confirmed by amyloid PET, which typically occurs within 6 to 18 months in approximately half of treated patients. Leqembi is given indefinitely under standard practice. Choice depends on the neurologist's judgment, the patient's logistical situation, and the comparative ARIA profile.
Do I need an amyloid PET scan before starting Kisunla? Yes, or alternatively a CSF biomarker confirming amyloid pathology. Beyond the initial diagnostic scan, Kisunla treatment also involves serial amyloid PET imaging at approximately 6-month and 12-month intervals to assess plaque clearance and trigger discontinuation under the FDA-label provision.
What is ARIA and what is the risk with Kisunla? Amyloid-related imaging abnormalities (ARIA) are MRI-detected findings of brain oedema (ARIA-E) or haemorrhages/microhaemorrhages (ARIA-H) that occur as a class effect of anti-amyloid antibody therapy. In the TRAILBLAZER-ALZ 2 pivotal trial, radiographic ARIA-E occurred in approximately 24 percent of Kisunla-treated patients, with symptomatic ARIA-E in approximately 6 percent. APOE epsilon-4 homozygotes carry substantially higher risk than non-carriers. Most ARIA resolves with temporary or permanent treatment discontinuation.
Why can Kisunla be stopped after amyloid clearance? The mechanism of Kisunla, which targets deposited amyloid plaque, lends itself to a finite treatment course: once amyloid plaque is cleared, continued antibody dosing has no further plaque to clear. The TRAILBLAZER-ALZ 2 trial design included an amyloid-PET-triggered discontinuation arm, and the FDA label permits clinicians to discontinue therapy once plaque clearance is confirmed. This is operationally and economically distinctive within the anti-amyloid class.
How is APOE genotype used in Kisunla decisions? The Kisunla label includes APOE genotype information to inform shared decision-making about ARIA risk. APOE epsilon-4 homozygotes face the highest ARIA risk and require the most intensive MRI surveillance. Some neurologists adjust the threshold for initiating treatment or use a different surveillance cadence. Genotyping is performed once, prior to initiation, with informed consent that addresses the implications for the patient and biological relatives.
Will Kisunla reverse my mother's Alzheimer's disease? No. Kisunla slows the rate of cognitive and functional decline; it does not reverse existing cognitive impairment. In the TRAILBLAZER-ALZ 2 trial, treatment slowed the rate of decline on the integrated AD Rating Scale by approximately 22 to 35 percent over 18 months versus placebo, with the larger effect in the low-tau subgroup. Families consider this benefit alongside the ARIA risk and the infusion logistics.
Can Kisunla be combined with donepezil or memantine? Yes. Combination with cholinesterase inhibitors and memantine is permitted and common; the mechanisms are distinct and complementary.
What about competing products in this class? Within the anti-amyloid antibody class, Leqembi (lecanemab, Eisai / Biogen) is the principal alternative, with a different binding target (soluble protofibrils plus insoluble fibrils) and a biweekly IV dosing schedule. Aducanumab (Aduhelm, Biogen) was effectively withdrawn from the US market in early 2024. Symptomatic therapy with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA antagonist memantine remains standard of care alongside or following anti-amyloid therapy. Reserve Meds coordinates whichever specific product the treating physician has prescribed.
Where Reserve Meds fits in Kisunla cases
Reserve Meds is a US-based concierge coordinator. We do not replace your neurologist or memory-disorders specialist, we do not replace the Saudi Food and Drug Authority (SFDA), and we do not replace your dispensing pharmacy or treating hospital. For Kisunla specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated cold-chain or cryogenic logistics with continuous temperature logging into Saudi Arabia, and assign a single named coordinator through the case.
For anti-amyloid antibody cases, our coordinator role spans the biomarker-workup, infusion-cadence, and MRI-surveillance arc rather than a single dispensing event: amyloid biomarker scheduling support, recurring shipments aligned to the dosing schedule, MRI cadence reminders, and ARIA reporting workflow with the treating neurologist or memory-disorders specialist. No prior Reserve Meds case experience for Kisunla is logged yet; standard NPP coordination under our neurology biologic playbook applies.
Next step
If your Saudi Arabia physician has prescribed Kisunla and you are weighing the cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.